Diabetic macular edema is swelling in the center of the retina caused by leaky blood vessels in diabetes. It is a leading reason people with diabetes lose reading vision. Today it is usually treated with repeated eye injections, often every one to two months at first. Researchers are testing whether a single gene therapy injection could make the eye produce its own long-lasting treatment.
What was presented
At the EURETINA 2026 congress in Vienna, retina specialist Arshad Khanani, MD, of Sierra Eye Associates, reviewed 2-year results from SPECTRA, a small phase 1/2 study of 4D-150, an investigational gene therapy from 4D Molecular Therapeutics given as one injection into the eye.
- Safety: Dr. Khanani called this the most important finding. No patient had intraocular inflammation. He noted that with other eye gene therapies, some patients with diabetic macular edema have had inflammatory events that led to permanent vision loss.
- Effect: He reported vision gains, improvements in retinal swelling, and a significant reduction in how many treatments patients needed.
He was clear about the limits: “Obviously, it’s a small phase 1/2 trial looking at safety, but it gives me hope that we can now take this treatment forward for our patients in larger studies.”
What comes next
A global phase 3 trial called 4SIGHT has started. It enrolls people with diabetic macular edema who have not been treated before. They receive loading doses and then a single 4D-150 injection, compared with aflibercept (Eylea) every 8 weeks. Dr. Khanani enrolled the first patient and said that, based on regulatory feedback, only one trial is required for this condition.
What to do now
- 4D-150 is investigational and not FDA approved.
- If you have diabetes, get a dilated eye exam at least yearly, or as often as your doctor advises.
- Keeping blood sugar, blood pressure, and cholesterol in range protects the retina.
- If you are on injections, keep every appointment.
Diabetic macular edema is managed by retina specialists; ask your eye doctor for a referral if needed. For more reading, see piineye.com.
Source: EURETINA 2026: 2-year SPECTRA results and the phase 3 programme for 4D-150 gene therapy in DMO (Ophthalmology Times, 10/02/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.